首页 › 基金 › Pivotal bioVenture Partners Investment Advisor LLC › RXRX
Pivotal bioVenture Partners Investment Advisor LLC 对 RXRX 的持仓历史
RECURSION PHARMACEUTICALCLASS A · 医疗保健
Pivotal bioVenture Partners Investment Advisor LLC 在 Q2 2026 的 13F 申报中披露持有 RXRX(RECURSION PHARMACEUTICALCLASS A)595,518 股,市值约 US$2.2M,约占其申报组合的 0.71%,在其申报持仓中市值排名第 13 位。 Pivotal bioVenture Partners Investment Advisor LLC 最近 7 个申报季度中有 7 个季度披露了 RXRX 持仓,最早可追溯至 Q4 2024。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
Pivotal bioVenture Partners Investment Advisor LLC 对 RXRX 的持仓演变
Pivotal bioVenture Partners Investment Advisor LLC 于 Q4 2024 首次披露 RXRX 持仓:595,518 股(约 US$4.0M)。 在 7 次申报中,Pivotal bioVenture Partners Investment Advisor LLC 的持股数量始终未变。 最近一期申报(Q2 2026)显示持股 595,518 股、市值约 US$2.2M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2024 | 595.52K | $4.03M | 新进 |
| Q1 2025 | 595.52K | $3.15M | 持有 |
| Q2 2025 | 595.52K | $3.01M | 持有 |
| Q3 2025 | 595.52K | $2.91M | 持有 |
| Q4 2025 | 595.52K | $2.44M | 持有 |
| Q1 2026 | 595.52K | $1.83M | 持有 |
| Q2 2026 | 595.52K | $2.19M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 RXRX 与 13F 数据
RXRX(RECURSION PHARMACEUTICALCLASS A)属于医疗保健行业。我们追踪的基金中还有 29 只申报持有 RXRX,申报仓位最大的包括:方舟投资 (US$151.7M), SOFTBANK GROUP CORP. (US$50.0M), MIC Capital Management UK LLP (US$35.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 RXRX 的基金
- 方舟投资 41.34M 股 · $151.71M · Q2 2026
- SOFTBANK GROUP CORP. 13.64M 股 · $50.05M · Q2 2026
- MIC Capital Management UK LLP 9.64M 股 · $35.39M · Q2 2026
- Data Collective IV GP, LLC 5.94M 股 · $21.80M · Q2 2026
- DCVC Opportunity Fund II GP, LLC 3.95M 股 · $14.50M · Q2 2026
更多关于 Pivotal bioVenture Partners Investment Advisor LLC
常见问题
How long has Pivotal bioVenture Partners Investment Advisor LLC held RXRX?
Pivotal bioVenture Partners Investment Advisor LLC has disclosed RXRX holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Pivotal bioVenture Partners Investment Advisor LLC's current position in RXRX?
As of Q2 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 595.52K shares of RXRX (RECURSION PHARMACEUTICALCLASS A), valued at $2.19M, representing 0.71% of its reported portfolio and ranking #13.
Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling RXRX?
In the latest 13F filing (Q2 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in RXRX.
Which other funds hold RXRX?
Other major institutional holders of RXRX include 方舟投资, SOFTBANK GROUP CORP., MIC Capital Management UK LLP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.